Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company, reported a net loss of $34.8 million for FY 2025 ended December 31, 2025, compared to $25.5 million in FY 2024, driven by increased research and development expenses of $21.2 million (up from $14.1 million) and general and administrative expenses of $16.0 million, totaling operating expenses of $37.1 million. No revenue was generated, consistent with its pre-commercial stage focused on (Z)-endoxifen development for breast cancer and rare diseases. Operating loss was $37.1 million, with interest income of $2.4 million partially offsetting losses, resulting in a loss before taxes of $34.8 million. Basic and diluted EPS was -$4 per share on 8.6 million weighted average shares. Balance sheet shows $41.3 million in cash and equivalents, $45.6 million total current assets, and $47.6 million total assets, with $39.4 million stockholders' equity. Net cash used in operations was $29.8 million, indicating a net decrease in cash of $29.8 million. Management states existing cash funds operations for the next 12 months but additional capital is needed long-term amid ongoing Phase 2 trials like Karisma-(Z)-endoxifen and I-SPY 2.

Key Takeaways